X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14) 14
male (13) 13
middle aged (13) 13
female (10) 10
index medicus (10) 10
aged (9) 9
diabetes (8) 8
endocrinology & metabolism (7) 7
type 2 diabetes (7) 7
diabetes mellitus, type 2 - drug therapy (6) 6
diabetes mellitus, type 2 - blood (5) 5
diabetes mellitus, type 2 - complications (5) 5
diabetics (5) 5
endothelial dysfunction (5) 5
care and treatment (4) 4
internal medicine (4) 4
medicine & public health (4) 4
metabolic diseases (4) 4
oxidative stress (4) 4
adult (3) 3
blood glucose - metabolism (3) 3
diabetes mellitus (3) 3
glycated hemoglobin a - metabolism (3) 3
hyperglycemia (3) 3
hypoglycemic agents - therapeutic use (3) 3
insulin-resistance (3) 3
monocytes (3) 3
monocytes - metabolism (3) 3
risk factors (3) 3
abdominal fat (2) 2
activation (2) 2
atherosclerosis (2) 2
blood glucose - drug effects (2) 2
cardiovascular diseases - prevention & control (2) 2
case-control studies (2) 2
cholesterol (2) 2
diabetes mellitus, type 2 - metabolism (2) 2
diabetes mellitus, type 2 - physiopathology (2) 2
diabetes therapy (2) 2
disease (2) 2
endothelin-1 - blood (2) 2
endothelium (2) 2
endothelium, vascular - drug effects (2) 2
erectile dysfunction (2) 2
follow-up studies (2) 2
glutathione (2) 2
impotence (2) 2
inflammation (2) 2
insulin - metabolism (2) 2
insulin resistance (2) 2
medical research (2) 2
medicine, experimental (2) 2
men (2) 2
metabolic syndrome (2) 2
monocytes - drug effects (2) 2
mortality (2) 2
nephropathy (2) 2
nitric-oxide (2) 2
nutrition & dietetics (2) 2
obesity (2) 2
peripheral vascular disease (2) 2
piperazines - administration & dosage (2) 2
polymerase activation (2) 2
purines - administration & dosage (2) 2
reactive oxygen species - metabolism (2) 2
sildenafil (2) 2
sildenafil citrate (2) 2
sulfones - administration & dosage (2) 2
treatment outcome (2) 2
urology (2) 2
urology & nephrology (2) 2
6-month (1) 1
abdominal ultrasonography (1) 1
abdominal ultrasonography; deep fat; echocardiography; glucagon-like peptide 1 receptor agonists; subcutaneous fat; type 2 diabetes; endocrinology; internal medicine; endocrinology, diabetes and metabolism (1) 1
abridged index medicus (1) 1
adhesion molecules (1) 1
adipokines (1) 1
adipokines - physiology (1) 1
adipokines; dietary polyphenols; gestational diabetes mellitus; mediterranean diet; microrna; molecular mechanisms; pufa; medicine; nutrition and dietetics (1) 1
adipose tissue - diagnostic imaging (1) 1
adipose tissue - drug effects (1) 1
adipose tissue - metabolism (1) 1
adp-ribosylation (1) 1
age of onset (1) 1
airway responsiveness (1) 1
alanine transaminase - blood (1) 1
alanine-aminotransferase (1) 1
allergy (1) 1
alpha-converting-enzyme (1) 1
alpha-enolase (1) 1
analysis (1) 1
angiotensin-ii (1) 1
animals (1) 1
annexins (1) 1
anticholesteremic agents (1) 1
antilipemic agents (1) 1
antioxidants (1) 1
antioxidants - administration & dosage (1) 1
aortic-stenosis (1) 1
arrhythmia (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 05/2012, Volume 125, Issue 19, pp. 2323 - 2333
Background-cGMP phosphodiesterase type 5 protein is upregulated in myocardial hypertrophy. However, it has never been ascertained whether phosphodiesterase... 
fibrosis | phosphodiesterase inhibitors heart failure | diabetes mellitus type 2 | cardiac magnetic resonance imaging | diabetic diastolic heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | PULMONARY-HYPERTENSION | ENDOTHELIAL DYSFUNCTION | SILDENAFIL CITRATE | AORTIC-STENOSIS | DIASTOLIC HEART-FAILURE | HYPERTROPHY | FLOW-MEDIATED DILATATION | NITRIC-OXIDE | VALVE-REPLACEMENT | PERIPHERAL VASCULAR DISEASE | TYPE-5 INHIBITION | Piperazines - administration & dosage | Diabetic Cardiomyopathies - drug therapy | Follow-Up Studies | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Magnetic Resonance Imaging - methods | Male | Purines - administration & dosage | Torsion, Mechanical | Sildenafil Citrate | Hypertrophy, Left Ventricular - pathology | Purines - adverse effects | Cardiac Imaging Techniques - methods | Hypertrophy, Left Ventricular - drug therapy | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Diabetes Mellitus, Type 2 - complications | Phosphodiesterase 5 Inhibitors - administration & dosage | Treatment Outcome | Piperazines - adverse effects | Diabetic Cardiomyopathies - pathology | Aged | Ventricular Remodeling - drug effects | Sulfones - administration & dosage | Care and treatment | Magnetic resonance imaging | Cardiomyopathy | Clinical trials | Diagnosis | Phosphodiesterases | Heart diseases | Health aspects | Methods
Journal Article
Journal Article
Acta Diabetologica, ISSN 0940-5429, 8/2015, Volume 52, Issue 4, pp. 727 - 732
Journal Article
European Urology, ISSN 0302-2838, 2007, Volume 52, Issue 6, pp. 1768 - 1776
Journal Article
Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2010, Volume 17, Issue 6, pp. 539 - 545
Aim: Type 2 diabetes increases the risk for cardiovascular disease, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) reduce... 
Oxidative stress | Monocytes | Diabetes | Statin therapy | C-REACTIVE PROTEIN | ACTIVATION | MYOCARDIAL-INFARCTION | CHOLESTEROL | MACROPHAGES | ATHEROSCLEROSIS | SCAVENGER RECEPTOR | INFLAMMATION | PERIPHERAL VASCULAR DISEASE | OXIDIZED-LDL | TRANSCRIPTION FACTOR
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article